Pharmaceutical treatment studies in autism and ADHD: A design based review of study quality

Journal of Pediatric Neurology

Volumn 5, Issue 3, 2007, Pages 189-197

  Wisniewski, Tami ^a   Brimacombe, Michael B ^a   Ming, Xue ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

ADHD; Autism; Design quality; Pharmacotherapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PEMOLINE; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEDATIVE AGENT; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DELIRIUM; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; INCREASED APPETITE; LIVER DISEASE; MEDICAL RESEARCH; MEDLINE; METHODOLOGY; PEER REVIEW; PRESCRIPTION; PROLACTIN BLOOD LEVEL; QUALITY CONTROL; SAMPLE SIZE; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; TIC; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 34547634440     PISSN: 13042580     EISSN: 18759041     Source Type: Journal    
DOI: 10.1055/s-0035-1557380     Document Type: Article

References (37)

1. L. Friedman, C.D. Furberg and D.L. DeMets, Fundamentals of Clinical Trials, New York. Springer-Verlag, 1998.
2. P.E. Tanguay, Pervasive developmental disorders: A 10-year review, J Am Acad Child Adolesc Psychiatry 39 (2000), 1079-1095.
3. P.S. Jensen, L. Kettle, M.T. Roper et al., Are stimulants over-prescribed? Treatment of ADHD in four US communities, J Am Acad Child Adolesc Psychiatry 38 (1999), 797-804.
4. B.H. King, Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders, J Autism Dev Disord 30 (2000), 439-445.
5. M. Olfson, S.C. Marcus, M.M. Weissman and P.S. Jensen, National trends in the use of psychotropic medications by children, J Am Acad Child Adolesc Psychiatry 41 (2002), 514-521.
6. D.A. Kube, M.C. Petersen and F.B. Palmer, Attention deficit hyperactivity disorder: Comorbidity and medication use, Clin Pediatr (Phila) 41 (2002), 461-469.
7. J.M. Zito, D.J. Safer, S. DosReis et al., Psychotropic practice patterns for youth: A 10-year perspective, Arch Pediatr Adolesc Med 157 (2003), 17-25.
8. R. Goodwin, M.S. Gould, C. Blanco and M. Olfson, Prescription of psychotropic medications to youths in office-based practice, Psychiatr Serv 52 (2001), 1081-1087.
9. A. Martin, L. Scahill, A. Klin and F.R. Volkmar, Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use, J Am Acad Child Adolesc Psychiatry 38 (1999), 923-931.
10. D.J. Safer, J.M. Zito and S. DosReis, Concomitant psychotropic medication for youths, Am J Psychiatry 160 (2003), 438-449.
11. L.L. Greenhill, P.S. Jensen, H. Abikoff et al., Developing strategies for psychopharmacological studies in preschool children, J Am Acad Child Adolesc Psychiatry 42 (2003), 406-414.
12. United States Food and Drug Administration. FDA Statement on recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees. Date posted: SHpt. 16, 2004. Retrieved from: http://www.fda.gov/bbs/topics/news/2004/NEW01116.html.
13. E.J. Garland, Facing the evidence: Antidepressant treatment in children and adolescents, CMAJ 170 (2004), 489-491.
14. M.M. Seltzer, M.W. Krauss, P.T. Shattuck G. Orsmond, A. Swe and C. Lord, The symptoms of autism spectrum disorders in adolescence and adulthood, J Autism Dev Disord 33 (2003), 565-581.
15. D.A. Lee, R. Lopez-Alberola and M. Bhattacharjee, Childhood autism: A circuit syndrome? Neurologist 9(2) (2003), 99-109.
16. B.J. Tonge, C. Dissanayake and A.V. Brereton, Autism: Fifty years on from Kanner, J Pediatr Child Health 30 (1994), 102-107.
17. W.A. Goldberg, K. Osaan, P.A. Filipek et al., Language and other regression: Assessment and timing, J Autism Dev Disord 33 (2003), 607-616.
18. M. Yeargin-Allsopp, C. Rice, T. Karapurkar, N. Doernberg, C. Boyle and C. Murphy, Prevalence of autism in a US metropolitan area, JAMA 289 (2003), 49-55.
19. J. Bertrand, A. Mars, C. Boyle, F. Bove, M. Yeargin-Allsopp and P. Decouflé, Prevalence of autism in a United States population: The Brick Township, New Jersey, investigation, Pediatrics 108 (2001), 1155-1161.
20. E. Schopler and J.M. Hennike, Past and present trends in residential treatment. J Autism Dev Disord 20 (1990). 291-298.
21. K.S. Langworthy-Lam, M.G. Aman and M.E. Van Bourgondien, Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina, J Child Adolesc Psychopharmacol 12 (2002), 311-321.
22. M.G. Aman, K.S. Lam and A. Collier-Crespin, Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio, J Autism Dev Disord 33 (2003), 527-534.
23. M.G. Aman, M.E. Van Bourgondien, P.L. Wolford and G. Sarphare, Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use, J Am Acad Child Adolesc Psychiatry 34 (1995), 1672-1681.
24. A. Martin, T. Van Hoof, D. Stubbe, T. Sherwin and L. Scahill, Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care, Psychiatr Serv 54 (2003), 72-77.
25. S.B. Schur, L. Sikich, R.L. Findling et al., Treatment recommendations for the use of antipsychotics for aggressive Youth (TRAAY). Pan I: A review, J Am Acad Child Adolesc Psychiatry 42 (2003), 132-144.
26. P.J. Santosh and G. Baird, Psychopharmacotherapy in children and adults with intellectual disability, Lancet 354 (1999), 233-242.
27. R.R. Fewell and B.A. Deutscher, Attention Deficit Hyperactivity Disorder in very young children: Early signs and interventions, Infants Young Child 14 (2002), 24-432.
28. A. Charach, A. Ickowicz and R. Schachar, Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 43 (2004), 559-567.
29. K. Kirby, V. Floriani and H. Bernstein, Diagnosis and management of attention-deficit/ hyperactivity disorder in children, Curr Opin Pediatr 13 (2001), 190-199.
30. K.C. Daley, Update on attention-deficit/hyperactivity disorder, Curr Opin Pediatr 16 (2004), 217-226.
31. E.H. Harel and W.D. Brown, Attention deficit hyperactivity disorder in elementary school children in Rhode Island: Associated psychosocial factors and medications used, Clin Pediatr (Phila) 42 (2003), 497-503.
32. J.M. McClellan and J.S. Werry, Evidence-based treatments in child and adolescent psychiatry: An inventory, J Am Acad Child Adolesc Psychiatry 42 (2003), 1388-1400.
33. L.E. Arnold, M.G. Aman, A. Martin et al. Assessment in multisite ranglomized clinical trials of patients with autistic disorder: The Autism RUPP Network, J Autism Dev Disord 30 (2000), 99-111.
34. Food and Drug Modernization Act of 1997 S. 830, 105th Cong. 1st Session, 1997.
35. Best Pharmaceuticals for Children Act S.1789 107th Cong. 1st Session, 2001.
36. Food add Drug Administration, Office of pediatric Therapeutics. Date visited: Oct. 8, 2004. RHtrieved from: http://www.fda.gov/oc/opt/ default.htm.
37. Pediatric Research Equity Act of 2003 S.650, 108th Cong. 1st Session, 2003.